Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population‐based cohort study

Benign Prostate Hyperplasia (BPH) has been associated with prostate cancer prevalent among men after 50 years of age, however, it is unclear whether the antidiabetic drug, metformin, can reduce prostate cancer for men with BPH. The insurance claims data of men aged 50 years or older, with both type...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuo, Yu‐Jui, Sung, Fung‐Chang, Hsieh, Po‐Fan, Chang, Hui‐Ping, Wu, Kun‐Ling, Wu, Hsi‐Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Cancer Prevention
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536940/
https://www.ncbi.nlm.nih.gov/pubmed/30968600
http://dx.doi.org/10.1002/cam4.2025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536940/
https://www.ncbi.nlm.nih.gov/pubmed/30968600
http://dx.doi.org/10.1002/cam4.2025

Ejemplares similares